ASSIGNMENT Course Code

ASSIGNMENT
Course Code: PHRM 407
Course Title: Pharmaceutical Biotechnology
SEC: 01
Submitted to:
Najneen Ahmed
Senior Lecturer
Department of Pharmacy
Submitted by:
Nishat Tasnim Diba
ID: 2016-1-70-070
Date of submission: 05-11-2018
PRODUCTION OF MONOCLONAL ANTIBODIES
BY USING
HYBRIDOMA TECHNOLOGY
Antibodies that are made by their identical immune cells and which are the clones of a unique parent cells are called Monoclonal Antibodies ((MABs).

Hybridoma Technology is one of the method by which monoclonal antibody is produced. By this process a large numbers of identical antibodies (MABs) are produced. There is a type of cell called Hybridomas which have been engineered to produce a desired antibody in large amounts, and to produce monoclonal antibodies. In 1975 two scientists, G. Kohler and C. Milstein discovered Hybridoma technology and in 1984 they were awarded Noble prize for physiology and medicine.

METHOD
Hybridoma, is produced by the injection of a specific antigen into a mouse, procuring the antigen-specific plasma cells (antibody- producing cell) from the mouse’s spleen and the subsequent fusion of this cell with a cancerous immune cell referred to as a malignant neoplasm(myeloma cell).

Soon after the spleen cells are isolated from the mammal’s spleen, the myeloma cells and the B cells are fused.

By this process hybrid cells are produced and it can be cloned to produce many identical daughter clones.

Immune cell products are then secreted from those daughter cells. When these antibodies come from only one type of cell (the hybridoma cell) they are called monoclonal antibodies.

This process can combine the qualities of the two different types of cells; the ability to grow continually, and to produce large amounts of pure antibody; that is the advantage of this process.

Figure: Production of MAbs by Hybridoma Technology
HAT Selection
HAT medium (Hypoxanthine Aminopterin Thymidine) is employed for preparation of monoclonal antibodies.

Laboratory animals (mice) are 1st exposed to associate substance to that we tend to have associate interest in uninflected an antibody against.

Once spleen cells are isolated from the vertebrate, the B cells are coalesced with immortalized malignant neoplasm cells that lack the HGPRT (hypoxanthine-guanine phosphoribosyl transferase) gene exploitation polythene glycol.

Fused cells are incubated within the HAT (Hypoxanthine Aminopterin Thymidine) medium.

Myeloma cells die, as they can’t turn out nucleotides by the de novo or salvage medium blocks the pathway that permits for nucleotide synthesis.

Unfused B cells die as they need a brief lifetime.

Solely the B cell-myeloma hybrids survive, since the HGPRT gene coming back from the B cells is purposeful.

These cells turn out antibodies (a property of B cells) and are immortal (a property of myeloma cells).

APPLICATION OF MONOCLONAL ANTIBODIES
Monoclonal antibodies are proving to be terribly helpful as diagnostic, imaging, and therapeutic reagents in clinical drugs.

Several monoclonal antibody diagnostic reagents currently obtainable are products for detection of pregnancy, diagnosis of various infective microorganisms.

By Immunoscintingraphy technique, radiolabeled Monoclonal Antibodies are used in diagnostic imaging for
Myocardial Infarction (MI)
Deep Vein Thrombosis (DVT)
Atherosclerosis
Cancer (Multiple Myeloma, Breast Carcinoma, Ovarian Carcinoma, Colorectal Carcinoma, Lung Carcinoma, Sarcoma etc.)
Therapeutic application of monoclonal antibodies includes infectious disease, cardiovascular disease, cancer, auto-immune disease and also transplantation of bone marrow and organs by different forms of MAbs naming
MAbs alone
Radioisotope immunoconjugates
Toxin and drug immunoconjugates

References